Index RUT
P/E -
EPS (ttm) -0.37
Insider Own 2.80%
Shs Outstand 5.46M
Perf Week -3.77%
Market Cap 514.01M
Forward P/E 9.97
EPS next Y 9.45
Insider Trans -13.60%
Shs Float 5.30M
Perf Month -9.95%
Enterprise Value 680.54M
PEG -
EPS next Q 2.27
Inst Own 95.01%
Short Float 3.48%
Perf Quarter -21.20%
Income -1.97M
P/S 2.13
EPS this Y -17.35%
Inst Trans 1.30%
Short Ratio 1.93
Perf Half Y -28.21%
Sales 240.98M
P/B 3.22
EPS next Y 9.21%
ROA -0.45%
Short Interest 0.18M
Perf YTD -28.55%
Book/sh 29.30
P/C 18.81
EPS next 5Y -5.81%
ROE -1.29%
52W High 155.12 -39.26%
Perf Year 6.85%
Cash/sh 5.01
P/FCF 12.08
EPS past 3/5Y - -
ROIC -0.79%
52W Low 84.32 11.74%
Perf 3Y -52.42%
Dividend Est. 0.64 (0.68%)
EV/EBITDA 16.66
Sales past 3/5Y 9.34% 15.41%
Gross Margin 55.32%
Volatility 4.96% 4.42%
Perf 5Y -57.61%
Dividend TTM 0.64 (0.68%)
EV/Sales 2.82
EPS Y/Y TTM 99.25%
Oper. Margin 6.78%
ATR (14) 4.79
Perf 10Y 3.68%
Dividend Ex-Date May 30, 2025
Quick Ratio 0.47
Sales Y/Y TTM 11.47%
Profit Margin -0.82%
RSI (14) 37.47
Recom 2.50
Dividend Gr. 3/5Y 0.00% 0.00%
Current Ratio 0.63
EPS Q/Q 97.23%
SMA20 -4.48%
Beta 0.88
Target Price 121.67
Payout -
Debt/Eq 1.21
Sales Q/Q 5.49%
SMA50 -13.59%
Rel Volume 3.14
Prev Close 98.67
Employees 730
LT Debt/Eq 0.56
Earnings May 28 BMO
SMA200 -23.40%
Avg Volume 95.41K
Price 94.22
IPO Feb 29, 1984
Option/Short No / Yes
EPS/Sales Surpr. -1.89% 0.38%
Trades
Volume 299,234
Change -4.51%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-28-24 Initiated
Wells Fargo
Underweight
$120
Jan-04-24 Upgrade
Evercore ISI
In-line → Outperform
$100 → $125
Jan-04-21 Downgrade
Evercore ISI
Outperform → In-line
$300
Nov-10-20 Initiated
KeyBanc Capital Markets
Sector Weight
$287
Oct-02-20 Initiated
JP Morgan
Neutral
$260
Dec-04-19 Initiated
Jefferies
Buy
Aug-26-19 Initiated
Evercore ISI
Outperform
$250
Jun-10-16 Downgrade
Sidoti
Buy → Neutral
May-28-25 09:15AM
08:23AM
(Associated Press Finance)
08:00AM
May-15-25 05:25PM
May-14-25 05:45PM
05:35PM
Loading…
May-13-25 05:35PM
May-08-25 08:45AM
Apr-07-25 03:00PM
Apr-03-25 03:51PM
Mar-26-25 12:00PM
Feb-13-25 08:31AM
Feb-11-25 12:20PM
Feb-04-25 09:15AM
08:17AM
(Associated Press Finance)
08:00AM
01:15PM
Loading…
Jan-17-25 01:15PM
Jan-06-25 03:00PM
Nov-07-24 09:20AM
08:27AM
(Associated Press Finance)
08:00AM
Oct-15-24 05:02PM
Oct-02-24 02:00PM
Aug-26-24 12:20PM
12:00PM
Aug-16-24 07:51AM
Aug-05-24 08:15AM
(Associated Press Finance)
08:00AM
Jul-31-24 09:14AM
Jul-08-24 02:00PM
Jun-05-24 11:53AM
06:38AM
Loading…
06:38AM
06:21AM
(Associated Press Finance)
06:00AM
May-31-24 06:00AM
May-22-24 06:00AM
Apr-08-24 08:00AM
Apr-04-24 06:24PM
Apr-01-24 10:27AM
Mar-15-24 07:00AM
Feb-19-24 10:23AM
Feb-05-24 09:20AM
08:36AM
08:22AM
(Associated Press Finance)
08:00AM
Jan-08-24 08:00AM
Jan-04-24 03:00PM
Jan-03-24 08:00AM
Dec-14-23 10:47AM
Nov-06-23 09:10AM
08:13AM
(Associated Press Finance)
08:00AM
Oct-16-23 03:00AM
Oct-03-23 08:00AM
Sep-22-23 08:09AM
06:20AM
Sep-15-23 01:10AM
Sep-13-23 01:37PM
Sep-11-23 11:21AM
Aug-24-23 04:02PM
Aug-10-23 01:32AM
Aug-03-23 09:35AM
08:27AM
08:00AM
Jul-31-23 07:50AM
Jul-05-23 03:00PM
Jun-21-23 08:00PM
11:50AM
May-25-23 09:25AM
08:14AM
08:00AM
May-22-23 01:16PM
May-02-23 06:23AM
Apr-26-23 08:00PM
Apr-03-23 06:15PM
06:00PM
07:42AM
Mar-13-23 08:00AM
Mar-09-23 08:00AM
Feb-21-23 05:36AM
Feb-14-23 09:00AM
Feb-13-23 12:45PM
08:00AM
Feb-06-23 09:55AM
08:36AM
Feb-01-23 12:43PM
06:43AM
Jan-27-23 06:00PM
Jan-19-23 06:15PM
Jan-17-23 04:33PM
Jan-13-23 06:00PM
Jan-12-23 09:40AM
Jan-11-23 06:26AM
Jan-09-23 06:15PM
Jan-03-23 05:00PM
Dec-28-22 06:51AM
05:20AM
Dec-18-22 04:48PM
Dec-16-22 11:59AM
Nov-23-22 12:20PM
Nov-17-22 08:04AM
Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Clinical Genomics segment division develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations. The Biopharmaceutical Development segment caters and sells automated systems for protein analysis and peptide synthesis solutions. The Calibration Solutions segment focuses on the quality control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications such as renal care, environmental and process monitoring, gas flow, air quality and torque testing, primarily in medical device manufacturing, pharmaceutical manufacturing, laboratory and hospital environments. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sakys John CFO Jun 21 '25 Option Exercise 95.82 1,036 99,270 15,498 Jun 25 09:14 AM Archbold Brian David SVP Operations Jun 21 '25 Option Exercise 95.82 844 80,872 2,792 Jun 25 09:05 AM Owens Gary M President and CEO Jun 21 '25 Option Exercise 95.82 3,301 316,302 54,022 Jun 24 10:12 AM Owens Gary M President and CEO Jun 18 '25 Option Exercise 92.99 8,707 809,664 54,531 Jun 20 05:39 PM Archbold Brian David SVP Operations Jun 18 '25 Option Exercise 92.99 2,556 237,682 3,114 Jun 20 05:31 PM Sakys John CFO Jun 18 '25 Option Exercise 92.99 2,840 264,092 15,705 Jun 20 05:22 PM Owens Gary M President and CEO Jun 15 '25 Option Exercise 0.00 4,426 0 47,763 Jun 18 11:27 AM Owens Gary M President and CEO Jun 16 '25 Sale 97.12 1,939 188,312 45,824 Jun 18 11:27 AM Archbold Brian David SVP Operations Jun 15 '25 Option Exercise 0.00 1,030 0 1,030 Jun 18 11:13 AM Archbold Brian David SVP Operations Jun 16 '25 Sale 97.12 472 45,840 558 Jun 18 11:13 AM Sakys John CFO Jun 15 '25 Option Exercise 0.00 793 0 12,839 Jun 18 10:59 AM Sakys John CFO Jun 16 '25 Sale 97.12 642 62,350 12,865 Jun 18 10:59 AM Archbold Brian David Officer Jun 16 '25 Proposed Sale 97.12 472 45,840 Jun 16 03:49 PM Owens Gary M Officer Jun 16 '25 Proposed Sale 97.12 1,939 188,311 Jun 16 03:47 PM Sakys John Officer Jun 16 '25 Proposed Sale 97.12 642 62,350 Jun 16 03:40 PM Owens Gary M President and CEO Mar 19 '25 Option Exercise 122.98 21,000 2,582,580 64,337 Mar 24 01:38 PM Owens Gary M President and CEO Mar 19 '25 Sale 123.91 21,000 2,602,110 43,337 Mar 24 01:38 PM Owens Gary M Officer Mar 19 '25 Proposed Sale 123.91 21,000 2,602,119 Mar 19 04:12 PM Owens Gary M President and CEO Oct 28 '24 Sale 113.62 2,518 286,085 45,888 Oct 29 08:18 PM Owens Gary M President and CEO Oct 29 '24 Sale 111.98 2,551 285,651 43,337 Oct 29 08:18 PM Owens Gary M Officer Oct 29 '24 Proposed Sale 111.98 2,551 285,652 Oct 29 03:47 PM Owens Gary M Officer Oct 28 '24 Proposed Sale 113.62 2,518 286,086 Oct 28 03:12 PM Archbold Brian David SVP Operations Sep 13 '24 Sale 125.00 1,499 187,375 0 Sep 16 12:14 PM Archbold Brian David Officer Sep 13 '24 Proposed Sale 125.00 1,499 187,381 Sep 13 04:35 PM Sakys John CFO Sep 01 '24 Option Exercise 0.00 1,037 0 12,500 Sep 06 12:46 PM Owens Gary M President and CEO Sep 01 '24 Option Exercise 0.00 3,301 0 38,292 Sep 06 12:21 PM Archbold Brian David SVP Operations Sep 01 '24 Option Exercise 0.00 845 0 1,885 Sep 06 12:12 PM Sullivan John James Director Sep 01 '24 Option Exercise 0.00 1,074 0 27,878 Sep 06 11:53 AM Tripeny R Tony Director Sep 01 '24 Option Exercise 0.00 1,074 0 2,679 Sep 06 11:43 AM Ladiwala Shiraz Shabanali Director Sep 01 '24 Option Exercise 0.00 1,574 0 3,074 Sep 06 11:35 AM Hall Shannon Director Sep 01 '24 Option Exercise 0.00 1,074 0 2,785 Sep 06 11:28 AM Alltoft Jennifer Sadie Director Sep 01 '24 Option Exercise 0.00 1,074 0 3,474 Sep 06 11:22 AM Capone Mark Christopher Director Aug 15 '24 Option Exercise 0.00 724 0 724 Aug 19 11:08 AM